News | May 01, 2025
Sigachi Industries signs MoU with Respilon Group
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Increases speed to market for drug developers working on nucleic acid therapeutics
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
